Form 4: Vigil Neuroscience Insider Disposes Shares on Sanofi Deal
Rhea-AI Filing Summary
Vigil Neuroscience (VIGL) – Form 4 insider filing
President & CEO Ivana Magovcevic-Liebisch reports the disposition of all directly held equity in connection with the 08/05/2025 closing of Vigil’s merger with Sanofi. At the effective time each outstanding share of common stock converted into the right to receive $8.00 cash plus one contingent value right (CVR) worth up to $2.00, subject to a clinical milestone.
The filing shows 222,687 common shares and eight option grants covering roughly 2.96 million shares marked “D” (disposed). Unvested options were accelerated, then: (i) options with strike < $8 were cashed out for the in-the-money spread and granted one CVR per underlying share; (ii) options with strike ≥ $8 and < $10 were exchanged solely for CVRs, with potential incremental cash if the milestone is achieved. Following these transactions the reporting person lists 0 derivative holdings and retains rights only to the merger consideration.
Positive
- Merger completion provides $8.00 immediate cash per share plus a potential $2 CVR upside.
- Unvested options fully accelerated and cashed-out, giving insiders and employees near-term liquidity.
Negative
- CEO disposes entire equity stake, leaving no ongoing insider share ownership post-merger.
- Options with strike prices ≥ $8 receive no guaranteed cash; value depends solely on milestone-contingent CVRs.
Insights
TL;DR – Filing confirms Sanofi deal closed; insider equity cancelled for $8 cash + $2 CVR.
The Form 4 evidences legal consummation of Sanofi’s take-over of Vigil Neuroscience. All shares and options of the CEO have been cancelled for the agreed merger consideration, removing any residual minority float. Acceleration of unvested options and cash‐out for in-the-money strikes simplifies post-closing integration and eliminates dilution for Sanofi. The cash element is immediate and the CVR provides upside linked to a clinical milestone, aligning holders with future R&D success. Overall impact is shareholder-friendly and signals completion of a material corporate event.
TL;DR – Cash exit secured; future value hinged on milestone-based CVR.
The disclosure finalises liquidity for VIGL investors via the $8 cash payout while leaving optionality through the $2 CVR. From a portfolio standpoint the position is effectively converted to cash plus a binary biotech kicker, allowing redeployment of capital with limited downside. The CEO’s full exit removes management alignment but is consistent with a change-of-control. Impact rated positive because cash settlement eliminates market risk on the equity.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Disposition | Stock Option Award (Right to Buy) | 369,351 | $0.00 | -- |
| Disposition | Stock Option Award (Right to Buy) | 210,629 | $0.00 | -- |
| Disposition | Stock Option Award (Right to Buy) | 405,494 | $0.00 | -- |
| Disposition | Stock Option Award (Right to Buy) | 43,271 | $0.00 | -- |
| Disposition | Stock Option Award (Right to Buy) | 282,000 | $0.00 | -- |
| Disposition | Stock Option Award (Right to Buy) | 370,000 | $0.00 | -- |
| Disposition | Stock Option Award (Right to Buy) | 463,000 | $0.00 | -- |
| Disposition | Stock Option Award (Right to Buy) | 485,000 | $0.00 | -- |
| Disposition | Common Stock | 222,687 | $0.00 | -- |
Footnotes (1)
- This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, Sanofi ("Parent"), and Vesper Acquisition Sub Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the terms of the Merger Agreement, on August 5, 2025 (the "Effective Time"), Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer continuing as the surviving corporation in the Merger and as a wholly owned subsidiary of Parent. At the Effective Time, each share of Issuer Common Stock issued and outstanding immediately prior to the Effective Time was converted into the right to receive (i) $8.00 per share of Common Stock in cash, without interest (the "Closing Amount") plus (ii) one contingent value right ("CVR"), representing the right to receive $2.00 payable in cash, conditioned upon satisfaction of a certain clinical milestone (together with the Closing Amount, the "Merger Consideration"). Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time, to the extent unvested, was accelerated and became fully vested. Each stock option having an exercise price per share that was less than the Closing Amount was cancelled and converted into the right to receive (i) an amount, without interest, equal to the product of (a) the total number of shares subject to such option immediately prior to the Effective Time, multiplied by (b) the excess of (1) the Closing Amount over (2) the exercise price per share under such option and (ii) one CVR for each share subject to such option. Each stock option having an exercise price per share that is equal to or greater than the Closing Amount but less than $10.00 was cancelled and converted into the right to receive one CVR for each share subject to such option immediately prior to the Effective Time, except that if the milestone is achieved in respect of the CVR, the cash amount to be paid to such option holder will be an amount equal to (i) $10.00 minus (ii) the exercise price per share subject to such option, subject to applicable tax withholdings
